Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,159
  • Shares Outstanding, K 16,100
  • Annual Sales, $ 8,960 K
  • Annual Income, $ -114,660 K
  • EBIT $ -76 M
  • EBITDA $ -74 M
  • 60-Month Beta 2.06
  • Price/Sales 2.12
  • Price/Cash Flow N/A
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 393.69% ( +70.56%)
  • Historical Volatility 120.87%
  • IV Percentile 89%
  • IV Rank 36.29%
  • IV High 1,075.58% on 02/05/24
  • IV Low 5.31% on 02/15/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 348
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,301
  • Open Int (30-Day) 3,436

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.71
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.93
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1438 +4.04%
on 12/20/24
3.0982 -61.59%
on 11/25/24
-1.5300 (-56.25%)
since 11/20/24
3-Month
1.1438 +4.04%
on 12/20/24
4.0413 -70.55%
on 11/14/24
-2.5000 (-67.75%)
since 09/20/24
52-Week
1.1438 +4.04%
on 12/20/24
8.9500 -86.70%
on 06/12/24
-2.5900 (-68.52%)
since 12/20/23

Most Recent Stories

More News
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients

AFM28 shows 40% complete remission rate in R/R AML patients with manageable safety profile in Phase 1 trial.Quiver AI SummaryAffimed N.V. announced promising results for its bispecific innate cell engager,...

AFMD : 1.1900 (+0.85%)
Affimed N.V. Reports Encouraging Efficacy of Acimtamig Combined with AlloNK® in R/R Classical Hodgkin Lymphoma at ASH Annual Meeting

Acimtamig with AlloNK® shows 86% response rate in relapsed/refractory classical Hodgkin lymphoma, with manageable safety.Quiver AI SummaryAffimed N.V. announced promising results from a study combining...

AFMD : 1.1900 (+0.85%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 1.1900 (+0.85%)
CSTL : 27.53 (+1.62%)
SPRO : 0.9551 (-4.30%)
ARTV : 11.11 (+11.10%)
Affimed Receives FDA RMAT Designation for Acimtamig and Artiva’s AlloNK® in Relapsed/Refractory Hodgkin Lymphoma Treatment

Affimed's acimtamig and Artiva's AlloNK® receive FDA RMAT designation for treating relapsed/refractory Hodgkin Lymphoma based on promising early data.Quiver AI SummaryAffimed N.V. announced that the U.S....

AFMD : 1.1900 (+0.85%)
Affimed N.V. Completes Enrollment in NSCLC Cohort and Prepares for Data Presentations at ASH 2024

Affimed N.V. reports on clinical trials, financial results, and updates on cash position through Q4 2025.Quiver AI SummaryAffimed N.V. announced the completion of enrollment in the EGFR wild-type non-small...

AFMD : 1.1900 (+0.85%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 1.1900 (+0.85%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 1.1900 (+0.85%)
Affimed N.V.: Q1 Earnings Snapshot

Affimed N.V.: Q1 Earnings Snapshot

AFMD : 1.1900 (+0.85%)
Affimed N.V.: Q3 Earnings Snapshot

Affimed N.V.: Q3 Earnings Snapshot

AFMD : 1.1900 (+0.85%)
Affimed N.V.: Q2 Earnings Snapshot

Affimed N.V.: Q2 Earnings Snapshot

AFMD : 1.1900 (+0.85%)

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

3rd Resistance Point 1.3516
2nd Resistance Point 1.3008
1st Resistance Point 1.2454
Last Price 1.1900
1st Support Level 1.1392
2nd Support Level 1.0884
3rd Support Level 1.0330

See More

52-Week High 8.9500
Fibonacci 61.8% 5.9680
Fibonacci 50% 5.0469
Fibonacci 38.2% 4.1258
Last Price 1.1900
52-Week Low 1.1438

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar